AARTIDRUGS vs PPLPHARMA: Stock Comparison

Aarti Drugs Limited vs Piramal Pharma Limited

Live data: 22 July 2026, 3:06 PM IST • Source: NSE and company filings

Piramal Pharma Limited is the larger company by market capitalisation. Aarti Drugs Limited shows a higher ROE, a higher dividend yield and faster revenue growth, while Piramal Pharma Limited shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Aarti Drugs Limited and Piramal Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AARTIDRUGS is more favourable on 11 of 13 scored metrics and PPLPHARMA on 2These counts are context-free and are not an overall rating.

Key Differences

Market Cap
PPLPHARMA is the larger company
₹23,554 Cr vs ₹3,769 Cr
P/E Ratio
PPLPHARMA has a lower P/E
-75.43x vs 20.04x
P/B Ratio
AARTIDRUGS has a lower P/B
2.52x vs 3.01x
EPS
AARTIDRUGS has higher earnings per share
₹21.81 vs ₹-2.45
Dividend Yield
AARTIDRUGS has a higher dividend yield
0.48% vs 0.08%
Revenue Growth (TTM YoY)
AARTIDRUGS has faster revenue growth
6.4% vs -0.1%
EPS Growth (TTM YoY)
PPLPHARMA has faster EPS growth
0% vs -12%
Qtr Sales Growth
AARTIDRUGS has stronger quarterly sales growth
6.43% vs -0.08%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIDRUGSPPLPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIDRUGSPPLPHARMA
Live Price₹411.55₹177.15
Day Change-3.6%-4.14%
Volume2.94 L79.43 L
52-Week High₹551.75₹212.39
52-Week Low₹318.95₹132.3
Distance from 52W High-25.41%-16.59%

Valuation

MetricAARTIDRUGSPPLPHARMA
Market Cap₹3,769 Cr₹23,554 Cr
P/E Ratio20.04x-75.43x
P/B Ratio2.52x3.01x
EPS₹21.81₹-2.45
Book Value₹169.79₹64.78
Dividend Yield0.48%0.08%

Growth

MetricAARTIDRUGSPPLPHARMA
Revenue Growth (TTM YoY)6.4%-0.1%
EPS Growth (TTM YoY)-12%0%
Qtr Sales Growth6.43%-0.08%
Qtr Profit Growth-12.2%-25%

Profitability & Leverage

MetricAARTIDRUGSPPLPHARMA
ROE13.4%-3.83%
ROCE11.9%2.52%
Net Margin7.6%-3.68%
Operating Margin12%10.4%
Debt to Equity0.37x0.7x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricAARTIDRUGSPPLPHARMA
Promoter Holding55.03%34.86%
FII Holding1.58% 0.57 pp30.18% 0.52 pp
DII Holding10.22% 0.1 pp15.61% 0.08 pp
Public Holding33.18% 0.48 pp19.01% 0.34 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aarti Drugs Limited and Piramal Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.